Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

1.360 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
Barclays Downgrades Gossamer Bio: Here's What You Need To Know
Via Benzinga
What 9 Analyst Ratings Have To Say About Gossamer Bio
Via Benzinga
ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday
Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Gossamer Bio
Via Benzinga
Analyst Ratings for Gossamer Bio
Via Benzinga
4 Analysts Have This to Say About Gossamer Bio
Via Benzinga
Dow Dips Over 500 Points; Nasdaq Down 2.5%
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 2.5% on Tuesday. 
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific... 
Via Benzinga
Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis
Via Benzinga
What 5 Analyst Ratings Have To Say About Gossamer Bio
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: 
Via Benzinga
What 4 Analyst Ratings Have To Say About Gossamer Bio
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
Where Gossamer Bio Stands With Analysts
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Souring Sentiment On Wall Street Sends Dow Down Triple Digits
Doubts over the Fed's next move are being compounded with renewed recession anxieties, and this sour sentiment is weighing on markets this afternoon. 
Via Talk Markets
S&P 500 Down Over 1%; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday. 
Via Benzinga
President Biden Is Bringing Taiwan Semi (TSM) Stock a HUGE Catalyst
Taiwan Semiconductor (TSM) stock is on the move Tuesday as investors prepare for President Joe Biden to visit the company's Arizona plant. 
Via InvestorPlace
Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?
GOSS stock is plunging over 70%. The company's hypertension drug reportedly failed to perform better than a competing treatment. 
Via InvestorPlace
Dow Drops 100 Points; US Trade Deficit Widens In October
U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Tuesday. 
Via Benzinga
Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
From Gossamer Bio, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial
Via Benzinga
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.